参考文献/References:
[1] Noronha-Ferreira C,Reis D,Cortez-Pinto H,et al.Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis[J].Dig Dis Sci,2019,64(9):2671-2683.
[2] Luca A,Caruso S,Milazzo M,et al.Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis[J].Radiology,2012,265(1):124-132.
[3] Delgado MG,Seijo S,Yepes I,et al.Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis[J].Clin Gastroenterol Hepatol,2012,10(7):776-783.
[4] Ai MH,Dong WG,Tan XP,et al.Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis[J].Eur J Gastroenterol Hepatol,2020,32(10):1395-1400.
[5] Chen H,Liu L,Qi X,et al.Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis[J].Eur J Gastroenterol Hepatol,2016,28(1):82-89.
[6] Chung JW,Kim GH,Lee JH,et al.Safety,efficacy,and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis:A propensity score matching analysis[J].Clin Mol Hepatol,2014,20(4):384-391.
[7] Pettinari I,Vukotic R,Stefanescu H,et al.Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis[J].Am J Gastroenterol,2019,114(2):258-266.
[8] Scheiner B,Stammet PR,Pokorny S,et al.Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function[J].Wien Klin Wochenschr,2017,130(13-14):446-455.
[9] Zhou T,Sun X,Zhou T,et al.Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients:A randomized controlled trial[J].Clin Transl Gastroenterol,2020,11(9):e00228.
[10] Lisman T,Porte RJ.Pathogenesis,prevention,and management of bleeding and thrombosis in patients with liver diseases[J].Res Pract Thromb Haemost,2017,1(2):150-161.
[11] Ogren M,Bergqvist D,Björck M,et al.Portal vein thrombosis:prevalence,patient characteristics and lifetime risk:A population study based on 23796 consecutive autopsies[J].World J Gastroenterol,2006,12(13):2115-2119.
[12] Nery F,Chevret S,Condat B,et al.Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis:Results of a longitudinal study[J].Hepatology,2015,61(2):660-667.
[13] Englesbe MJ,Kubus J,Muhammad W,et al.Portal vein thrombosis and survival in patients with cirrhosis[J].Liver Transpl,2010,16(1):83-90.
[14] Violi F,Corazza GR,Caldwell SH,et al.Portal vein thrombosis relevance on liver cirrhosis:Italian venous thrombotic events registry[J].Intern Emerg Med,2016,11(8):1059-1066.
[15] 祁兴顺,杨 玲.肝硬化门静脉血栓管理专家共识(2020年,上海)[J].临床肝胆病杂志,2020,36(12):2667-2674.
[16] Loffredo L,Pastori D,Farcomeni A,et al.Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:A systematic review and meta-analysis[J].Gastroenterology,2017,153(2):480-487.
[17] Qi X,De Stefano V,Li H,et al.Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis:A systematic review and meta-analysis of observational studies[J].Eur J Intern Med,2015,26(1):23-29.
[18] Ghazaleh S,Beran A,Aburayyan K,et al.Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis:A systematic review and meta-analysis[J].Ann Gastroenterol,2021,34(1):104-110.
[19] Werner KT,Sando S,Carey EJ,et al.Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation:Outcome of anticoagulation[J].Dig Dis Sci,2013,58(6):1776-1780.
[20] Chen H,Turon F,Hernández-Gea V,et al.Nontumoral portal vein thrombosis in patients awaiting liver transplantation[J].Liver Transpl,2016,22(3):352-365.
[21] Cerini F,Vilaseca M,Lafoz E,et al.Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats[J].J Hepatol,2016,64(4):834-842.
[22] Villa E,Cammà C,Marietta M,et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology.2012,143(5):1253-1260.
[23] 杨 娟,马 佳,马莉娜.低分子肝素钙预防断流术后门静脉血栓的临床观察[J].陕西医学杂志,2017,46(8):1121-1123.
[24] Intagliata NM,Henry ZH,Maitland H,et al.Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation[J].Dig Dis Sci,2016,61(6):1721-1727.
相似文献/References:
[1]杨 威,于庆生△,潘晋方,等.肝豆状核变性合并脾功能亢进患者行脾切除术中血小板水平对手术及预后的影响研究*[J].陕西医学杂志,2020,49(11):1403.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.009]
YANG Wei,YU Qingsheng,PAN Jinfang,et al.Influence of platelet level during splenectomy in patients with hepatolenticular degeneration and hypersplenism on the operation and prognosis[J].,2020,49(4):1403.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.009]
[2]王小芳,张利军.可溶性人髓系细胞触发受体1、可溶性血红蛋白清道夫受体、降钙素原表达水平对肝硬化合并自发性细菌性腹膜炎的诊断价值[J].陕西医学杂志,2021,50(12):1525.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.014]
[3]郭武辉,张 华.血清T淋巴细胞亚群检测在肝硬化合并真菌性血流感染中的诊断价值[J].陕西医学杂志,2021,50(12):1570.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.026]
GUO Wuhui,ZHANG Hua.Diagnostic value of serum T lymphocyte subsets detection in liver cirrhosis complicated with fungal bloodstream infection[J].,2021,50(4):1570.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.026]
[4]刘 杰,闵林玲,潘 金,等.经颈静脉肝内门腔静脉分流术与经皮肝穿刺胃冠状静脉栓塞术治疗肝硬化食管胃底静脉曲张破裂出血疗效对比研究[J].陕西医学杂志,2023,52(9):1191.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.017]
LIU Jie,MIN Linling,PAN Jin,et al.Comparative study of TIPS and PTVE in treatment of esophageal and gastric varices bleeding in liver cirrhosis[J].,2023,52(4):1191.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.017]
[5]杨金艳,李飞飞,谢元元,等.肝硬化上消化道出血患者预后营养指数与病情严重程度和短期预后相关性研究[J].陕西医学杂志,2023,52(11):1530.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.017]
[6]王 婷,邹百仓,董 蕾,等.核苷类似物治疗乙型肝炎肝硬化并发食管静脉曲张临床价值研究[J].陕西医学杂志,2024,(5):671.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.021]
WANG Ting,ZOU Baicang,DONG Lei,et al.Value of nucleoside analogues in the treatment of hepatitis B cirrhosis complicated with esophageal varices[J].,2024,(4):671.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.021]